ZNTL vs. PLRX, BCAX, PRTA, CRMD, QURE, DNTH, ETNB, CGEM, PHAR, and LENZ
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), Prothena (PRTA), CorMedix (CRMD), uniQure (QURE), Dianthus Therapeutics (DNTH), 89bio (ETNB), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.
Zentalis Pharmaceuticals vs.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Pliant Therapeutics received 16 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote.
Zentalis Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 346.43%. Pliant Therapeutics has a consensus target price of $40.50, indicating a potential upside of 261.28%. Given Zentalis Pharmaceuticals' higher probable upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Pliant Therapeutics.
Zentalis Pharmaceuticals' return on equity of -43.91% beat Pliant Therapeutics' return on equity.
In the previous week, Pliant Therapeutics had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 5 mentions for Pliant Therapeutics and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.93 beat Pliant Therapeutics' score of 0.54 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Pliant Therapeutics has higher revenue and earnings than Zentalis Pharmaceuticals. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zentalis Pharmaceuticals has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
97.3% of Pliant Therapeutics shares are owned by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Pliant Therapeutics beats Zentalis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ZNTL) was last updated on 1/18/2025 by MarketBeat.com Staff
Free ZNTL Stock Alerts